SAN DIEGO, Dec. 8 Orexigen(R) Therapeutics, Inc.(Nasdaq: OREX), a biopharmaceutical company focused on the treatment ofobesity, today announced that the Company will be speaking at the RBC CapitalMarkets Investor Conference. The presentation will be a panel format, titled"Shrinking the Obesity Epidemic." The details are as follows:
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on thetreatment of obesity. The Company's lead combination product candidates areContrave, which is in Phase 3 clinical trials, and Empatic, which is in thelater stages of Phase 2 clinical development. Each product candidate isdesigned to act on a specific group of neurons in the central nervous systemwith the goal of achieving appetite suppression and sustained weight loss.Further information about the company can be found at http://www.orexigen.com.Date: Wednesday, December 10 Time: 11:00 a.m. - 11:55 a.m. Eastern Location: Westin Times Square Hotel, New York
SOURCE Orexigen Therapeutics, Inc.